Premium
Adhesion molecules: a new target for immunoliposome‐mediated drug delivery
Author(s) -
Bloemen P.G.M.,
Henricks P.A.J.,
van Bloois L.,
van den Tweel M.C.,
Bloem A.C.,
Nijkamp F.P.,
Crommelin D.J.A.,
Storm G.
Publication year - 1995
Publication title -
febs letters
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.593
H-Index - 257
eISSN - 1873-3468
pISSN - 0014-5793
DOI - 10.1016/0014-5793(94)01350-a
Subject(s) - umbilical vein , drug delivery , monoclonal antibody , liposome , adhesion , icam 1 , cell adhesion molecule , targeted drug delivery , chemistry , cell adhesion , microbiology and biotechnology , in vitro , antibody , medicine , immunology , biochemistry , biology , organic chemistry
The anti‐ICAM‐1 monoclonal antibody F10.2 was conjugated to liposomes to target to cells expressing the cell adhesion molecule ICAM‐1. We demonstrate that F10.2 immunoliposomes bind to human bronchial epithelial cells (BEAS‐2B) and human umbilical vein endothelial cells (HUVEC) in a specific, dose‐ and time‐dependent manner. It appears that the degree of ICAM‐1 expression is the limiting factor in the degree of immunoliposome binding to the cells. These results are a first step in the strategy for specific drug delivery to target sites characterised by increased expression of adhesion molecules.